Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Dr. Steven R. Miller Ph.D.

Executive Vice President, Chief Operating Officer & Chief Scientific Officer

Mr. Jeffrey  Del Carmen

Executive Vice President & Chief Commercial Officer

Mr. Pete  Curry Sr.

Vice President of Sales

Dr. Gary  Ingenito M.D., Ph.D.

Chief Medical & Regulatory Officer

Mr. Richard John  Daly M.B.A.

President, Chief Executive Officer & Director

Dr. Preethi  Sundaram Ph.D.

Chief Strategy Officer

Ms. Mary  Coleman

Vice President & Head of Investor Relations

Mr. Michael W. Kalb CPA

Executive Vice President, Treasurer & Chief Financial Officer

Dr. Stanley  Iyadurai M.D., Ph.D.

Senior Vice President of Medical Affairs & Drug Discovery

Mr. Brian  Elsbernd J.D.

Chief Compliance Officer & Chief Legal Officer

バイオテクノロジー

Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. 経営体制

経営情報